Request Trial
shutterstock_1625917948_nitpicker
nitpicker / Shutterstock.com
11 October 2021Big Pharma

English High Court finds Bayer patent obvious in win for Teva

The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
Report reveals surge of AI adoption in IP but lawyers remain cautious
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Big Pharma
Sun Pharma and BMS lead 2025 ANDA litigation
10 November 2025   According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025

More features

Senior four-partner team leaves A&O Shearman
Final call: Who are the world’s best in-house counsel?
ITC to probe Oura Ring after Samsung retaliates, seeking import ban
Speciality pharma firm stumbles on bid to enforce Belbuca ruling
Italian medtech startup beats larger US rival in UPC dispute
Senior USPTO solicitor steps into private practice
Goodwin targets transatlantic patent work with London hire
Bayer secures key Denmark ruling as Xarelto faces expiry pressure